Stock UTHR UNITED THERAPEUTICS CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

All News United Therapeutics Corporation

Equities

UTHR

US91307C1027

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-08 pm EDT 		5-day change 1st Jan Change
316.9 USD +0.74% Intraday chart for United Therapeutics Corporation -0.66% +44.11%
Jul. 08 UBS Adjusts Price Target on United Therapeutics to $370 From $300, Maintains Buy Rating MT
Jul. 01 United Therapeutics Corporation(NasdaqGS:UTHR) added to Russell 1000 Defensive Index CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
FDA move illuminates key role of telomere targeting as a viable therapeutic strategy for cancer treatment
AQ
UBS Adjusts Price Target on United Therapeutics to $370 From $300, Maintains Buy Rating
MT
United Therapeutics Corporation(NasdaqGS:UTHR) added to Russell 1000 Defensive Index
CI
United Therapeutics Corporation(NasdaqGS:UTHR) added to Russell 1000 Value-Defensive Index
CI
United Therapeutics Insider Sold Shares Worth $2,395,035, According to a Recent SEC Filing
MT
United Therapeutics Insider Sold Shares Worth $2,285,941, According to a Recent SEC Filing
MT
United Therapeutics Corporation Announces Election of Jan Malcolm to its Board of Directors
BU
United Therapeutics Corporation Announces Board Changes
CI
Tempus Announces Collaboration with United Therapeutics to Study Use of AI to Detect Patients at Risk for Pulmonary Hypertension
AQ
Tempus, United Therapeutics Launch Collaboration to Use AI to Detect Risk of Pulmonary Hypertension
MT
Tempus AI, Inc. Announces Collaboration with United Therapeutics to Study Use of AI to Detect Patients at Risk for Pulmonary Hypertension
CI
United Therapeutics Insider Sold Shares Worth $1,033,984, According to a Recent SEC Filing
MT
United Therapeutics Insider Sold Shares Worth $1,027,716, According to a Recent SEC Filing
MT
Transcript : United Therapeutics Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 04:00 PM
Wells Fargo Raises Price Target on United Therapeutics to $350 From $325, Maintains Overweight Rating
MT
Groundbreaking Study by MAIA Biotechnology (NYSE: MAIA) Indicates Promising New Treatment for Advanced Lung Cancer
AQ
United Therapeutics Corporation to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
BU
Liquidia's Yutrepia Launch Cleared as Court Denies Injunction
MT
Manufacturers Are "Winning" In The 340B Drug Discount Dispute
AQ
United Therapeutics Insider Sold Shares Worth $545,800, According to a Recent SEC Filing
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. UTHR Stock
  4. News United Therapeutics Corporation